.svg){kind=small}
The introduction of the EU Joint Clinical Assessment (JCA) marks a pivotal moment, offering the opportunity to integrate the voices of patients more effectively into HTA and reimbursement decisions. However, challenges remain, particularly around the proactive inclusion of patient perspectives and timely data generation.
The Role of Patients in JCA: From Token to Influencer
Patients are now recognized as pivotal stakeholders in JCAs, with opportunities to contribute to assessment scopes, provide feedback on drafts, and share expert insights during meetings. Yet, this participation is often limited to "upon invitation" scenarios, leaving patient voices reactive rather than proactive. True progress will come when patient engagement is fully embedded as an early, integral part of HTA processes.
Timing Is Everything: Generating Patient-Centric Data Early
One of the most pressing challenges is the generation of patient-relevant data before HTA submissions. Late-stage efforts to include patient perspectives often fall short. Early patient involvement enables the collection of real-world evidence, patient preference information, and insights into the lived experience of disease. This data strengthens dossiers and aligns outcomes with what matters most to patients.
Bridging the Gaps: How We Support Meaningful Engagement
We specialize in navigating the complexities of patient engagement in Europe. Our patient2decide methodology empowers companies to integrate patient preferences into clinical trials, regulatory submissions, and HTA processes. From designing accessible study protocols to collecting robust patient-reported outcomes (PROs), we ensure that patient input is not just included but prioritized.
Why It Matters: Smarter Decisions, Better Outcomes
Aligning medical innovation with patient needs benefits everyone. A striking example from a depression study highlights this disparity: while experts emphasized remission, patients prioritized response—feeling some relief even if not fully cured. Incorporating such insights leads to therapies that are not only clinically effective but also resonate with patients' real-world experiences.
As Europe embraces a more unified HTA system, the question remains: will patients be passengers or co-pilots in this journey? At admedicum, we advocate for the latter, ensuring that patient engagement is not just a box-ticking exercise but a transformative approach to healthcare decision-making.
